Abstract
Glomerular disease involves a heterogeneous group of entities that are characterized by loss of the architecture and function of the glomerulus and this can be caused by immunity, infectious and paraneoplastic etiologies. The aforementioned can be identified in histopathological studies. The recognition of this entity during pregnancy represents a diagnostic challenge due to the superposition of physiological changes, the development of autoimmune diseases and / or genetic disease, among others. Clinical manifestations can be into specific syndromic groups; however we can find indistinguishable manifestations and overlapping of this. When the disease is present its common to find rapidly establishment and unfavorable evolution about renal function. With this it’s necessary to complete studies involving the initial clinical approach until histopathological findings with the goal to find primary and secondary causes. As it’s known primary glomerulonephritis is not the most frequent in pregnancy, the accuracy in the diagnosis and the proper classification allows the direct and soon management. In this case report we describe 2 pregnant women with primary glomerular disease with discrepancy in their diagnosis. We talk about manifestations during pregnancy, the algorithm used in the diagnosis and finally the initial treatment and the maintenance used in these patients.
References
Couser WG. Glomerulonephritis. Vol. 353, Lancet. Elsevier Limited; 1999. 1509–15. DOI: https://doi.org/10.1016/S0140-6736(05)75849-9
González L, Cantillo J. Diagnóstico en enfermedad glomerular del adulto. Acta Médica Colombiana. 2013; 38:101–7. DOI: https://doi.org/10.36104/amc.2013.294
García Herrera HG, Restrepo Valencia CA, Buitrago Villa CA. Características clínicas e histológicas de las enfermedades parenquimatosas renales en una muestra de biopsias renales obtenidas entre el año 2002 y el 2017 en el departamento de Caldas, Colombia. Revista colombiana de nefrologia. 2018; 2:107-117. DOI: http://dx.doi.org/10.22265/acnef.0.0.300
Blom K, Odutayo A, Bramham K, Hladunewich MA. Pregnancy and glomerular disease: A systematic review of the literature with management guidelines. Clinical Journal of the American Society of Nephrology. 2017. 12; 1862-1872. DOI: https://doi.org/10.2215/CJN.00130117
Moroni G, Ponticelli C. Rapidly progressive crescentic glomerulonephritis: Early treatment is a must. Autoimmunity Reviews. 2014. 13; 723-9. DOI: https://doi.org/10.1016/j.autrev.2014.02.007
Smith RJH, Appel GB, Blom AM, Cook HT, D’Agati VD, Fakhouri F, et al. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nature Reviews Nephrology. 2019. 15; 129–143. DOI: https://doi.org/10.1038/s41581-018-0107-2
Smith RJH, Alexander J, Barlow PN, Botto M, Cassavant TL, Cook HT, et al. New approaches to the treatment of dense deposit disease. Journal of the American Society of Nephrology. 2000. 18; 2447–2456. DOI: https://doi.org/10.1681/ASN.2007030356
Pickering MC, D’agati VD, Nester CM, Smith RJ, Haas M, Appel GB, et al. C3 glomerulopathy: Consensus report. In: Kidney International. 2013. 84; 1079–1089. DOI: https://doi.org/10.1038/ki.2013.377
Ravindran A, Fervenza FC, Smith RJH, De Vriese AS, Sethi S. C3 Glomerulopathy: Ten Years’ Experience at Mayo Clinic. Mayo Clin Proc. 2018. 93; 991-1008. DOI: https://doi.org/10.1016/j.mayocp.2018.05.019
Khalighi MA, Wang S, Henriksen KJ, Bock M, Keswani M, Meehan SM, et al. Revisiting post-infectious glomerulonephritis in the emerging era of C3 glomerulopathy. Clin Kidney J. 2016. 9; 397–402. DOI: https://doi.org/10.1093/ckj/sfw032
Aringer, M. et al. European League Against Rheumatism/American College ofRheumatology classication criteria for systemic lupus erythematosus. Arthritis &Rheumatology, Arthritis Rheumatol. 2019. 71;1400-1412. DOI: https://doi.org/10.1136/annrheumdis-2018-214819
Hou J, Markowitz GS, Bomback AS, Appel GB, Herlitz LC, Barry Stokes M, et al. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int. 85; 450–456 2014. DOI: https://doi.org/10.1038/ki.2013.340
Piccoli GB, Cabiddu G, Attini R, Vigotti FN, Maxia S, Lepori N, et al. Risk of adverse pregnancy outcomes in women with CKD. J Am Soc Nephrol. 2015; 26: 2011-2022. DOI: https://doi.org/10.1681/ASN.2014050459
Smyth A, Oliveira G, Lahr B, Bailey K, Norby S, Garovic V. A systematic review and meta-analysis ;of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clinical Journal of the American Society of Nephrology, 2010; 5: 2060-2068. DOI: https://doi.org/10.2215/CJN.00240110
Moroni G, Doria A, Giglio E, Tani C, Zen M, Strigini F, et al. Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. J Autoimmun. 2016; 74: 6–12. DOI: https://doi.org/10.1155/2018/2413637
Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. In: Kidney International. 2019; 95: 281-295. DOI: https://doi.org/10.1016/j.kint.2018.11.008
Rabasco C, Cavero T, Román E, Rojas-Rivera J, Olea T, Espinosa M, et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int. 2015; 88:1153-60. DOI: https://doi.org/10.1038/ki.2015.227
Avasare RS, Canetta PA, Bomback AS, Marasa M, Caliskan Y, Ozluk Y, et al. Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: A case series. Clin J Am Soc Nephrol. 2018; 13: 406–413. DOI: https://doi.org/10.2215/CJN.09080817
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.